Wolfgang Janni, MD, PhD, on Early Breast Cancer and Bisphosphonate Treatment: Results From the SUCCESS A Trial

2017 San Antonio Breast Cancer Symposium

Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival when compared with 2 years of treatment (Abstract GS1-06).

Aug

Today In Oncology

FDA Approves Nivolumab for Certain Patients With Previously Treated Small Cell Lung Cancer

BRCA Testing in Medically Underserved Women in Southeastern United States

FDA Accepts Biologics License Application, Grants Priority Review for Tagraxofusp in Rare Hematologic Malignancy

Functional and Social Independence in Survivors of Pediatric CNS Tumors

Bendamustine Followed by Obinutuzumab Plus Venetoclax in Treatment-Naive and Relapsed/Refractory CLL

;